Potential of Icosabutate as a Novel Approach to the Treatment of NASH Highlighted in Late-Breaker At The International Liver Congress™ 2018
Icosabutate, a structurally engineered fatty acid, displays optimised phamacokinetics for targeting both metabolic and inflammatory pathways in the liver, both wit...



























